Sat.Jan 27, 2024 - Fri.Feb 02, 2024

article thumbnail

Patient Perspective: Jamie Troil Goldfarb shares her clinical trial experience [video]

Antidote

For individuals living with a condition like melanoma, volunteering to participate in a clinical trial can be a rewarding experience. Not only will patients be able to gain access to potential new treatments, but they will also be directly contributing to research that can save lives — something that Jamie Troil Goldfarb has experienced firsthand. Jamie received a diagnosis of stage IV melanoma in 2011, only 11 weeks after giving birth to her child.

article thumbnail

Navigating clinical trial operations in the era of collaboration

Pharmaceutical Technology

The upcoming OCT West Coast 2024 conference will feature experts talking about emerging techologies, clinical trial operations for pharma and medical devices, and patient participation in studies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How to achieve patient centricity in clinical trial listings

Antidote

Facilitating medical research relies on patient participation, yet research protocols often overlook the patient perspective. Improving patient centricity in clinical trials demands prioritizing the patient experience.

article thumbnail

Pharma's Journey with Patient Family Advisory Councils

Pharmaceutical Commerce

Including patient and family feedback in our discussions will help shape our understanding of their perception of provided care and services and how we operate as a whole.

52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Setting up trials in APAC and Middle East can boost patient recruitment

Pharmaceutical Technology

Setting up trial sites in countries with unmet clinical needs can lead to higher patient recruitment, compared to established trial hubs.

Trials 130
article thumbnail

The secret to successful patient influencer marketing? Authenticity

pharmaphorum

Reverba offers innovative patient engagement solutions and strategies that utilise the power of authentic patient influencers. Discover the secret to successful patient influencer marketing and how it can benefit your healthcare organisation.

Marketing 118

More Trending

article thumbnail

Merck inks research deal with Culmination Bio to leverage ‘powerful’ patient data platform

BioPharma Reporter

Merck has signed a R&D collaboration deal with data and technology company Culmination Bio, a spinoff from Intermountain Health.

article thumbnail

Addressing Clinical Trial Complexity With More Robust Site Support

WCG Clinical

Site-Enablement-Infographic Download Benchmark site performance for your study Interested to see how the investigators in your current or planned studies match up against the historic performance of all available investigators for the therapeutic area of the study? Complete the form to schedule a consultation with WCG. We’ll share benchmark data from the WCG Knowledge Base, analyze your results, and share some of the common practices of top performers.

article thumbnail

Merck is on the lookout for more opportunities within immunology

Pharmaceutical Technology

At the JP Morgan Healthcare conference, Merck (MSD) indicated its eagerness to continue to establish its place in the immunological space.

362
362
article thumbnail

CAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in autoimmune disease

Bio Pharma Dive

Since a landmark paper in 2022, drugmakers have begun nearly a dozen trials of cell therapies for lupus, with more set to start. Here’s why their efforts are worth watching.

Trials 354
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

January 31, 2024: Improving the Public’s Understanding of the FDA, in This Week’s PCT Grand Rounds

Rethinking Clinical Trials

In this Friday's PCT Grand Rounds, Susan Winckler of the Reagan-Udall Foundation for the FDA will present "Strategies for Improving Public Understanding of FDA and the Products It Regulates: Why Should We Care, and What Might We Do?" The Grand Rounds session will be held on Friday, February 2, 2024, at 1:00 pm eastern. Winckler is the chief executive officer of the Reagan-Udall Foundation for the FDA, a nonprofit organization created by Congress “to advance the mission of the FDA to modernize me

Cosmetics 162
article thumbnail

Study reveals SARS-CoV-2 can infect dopamine neurons causing senescence

Pharma Times

Dopamine neuron senescence is a hallmark of Parkinson’s disease

Medicine 155
article thumbnail

Moderna leads the development of mRNA vaccines in infectious diseases

Pharmaceutical Technology

The rapid sequencing of the SARS-CoV-2 and the subsequent development of mRNA vaccines led to the authorisation of the first of these vaccines in late 2020.

Vaccine 278
article thumbnail

Non-opioid drug from Vertex cuts pain in major trial tests

Bio Pharma Dive

The company plans to soon ask the FDA for approval of the drug, which it has pitched as a safer alternative to addictive opioid painkillers.

Drugs 340
article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

Novartis calls time on Tim3 drug sabatolimab in MDS

pharmaphorum

Novartis ends development of Tim3 antibody sabatolimab in myelodysplastic syndromes after failed phase 3 trial.

Antibody 137
article thumbnail

Cancer treatment could identify patients most likely to respond to cancer drugs

Pharma Times

Tumours with high mtDNA mutations more likely to respond to Opdivo

Drugs 148
article thumbnail

GSK seeks to extend RSV vaccine use in adults aged 50-59

Pharmaceutical Technology

The EMA has accepted GSK’s regulatory application seeking expansion of its RSVvaccine, Arexvy, to include adults aged 50 to 59 years.

Vaccine 264
article thumbnail

Brain drug developer Alto Neuroscience prices $129M IPO

Bio Pharma Dive

The California biotech is the third this year to go public, following stock offerings from CG Oncology and Arrivent Biopharma.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Pfizer's layoff campaign ramps back up with dozens of SF-area cuts expected next month

Fierce Pharma

The start of the new year doesn’t seem to have dulled the zeal of Pfizer’s global cost-cutting campaign, which has already left hundreds of jobs in its wake. | Come mid-February, Pfizer will lay off some 52 employees at a facility in South San Francisco, according to a recent Worker Adjustment and Retraining Notification Act alert. The site is the former headquarters of Global Blood Therapeutics.

137
137
article thumbnail

International consortium identifies biomarkers for cardiovascular disease in diabetes

Pharma Times

Type 2 diabetes is estimated to affect 462 million people worldwide

147
147
article thumbnail

Keytruda remains Merck & Co’s biggest 2023 success story as patent expiry looms

Pharmaceutical Technology

Merck & Co (MSD) has reported a 1% revenue increase from 2022, and may face setbacks in the next few years from top-selling drugs.

Drugs 262
article thumbnail

AstraZeneca, Daiichi aim for first pan-tumor ADC approval

Bio Pharma Dive

The FDA is reviewing the companies’ application for a “tumor agnostic” indication for their drug Enhertu, which would break new ground for antibody-drug conjugates.

Antibody 314
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Grand Rounds January 26, 2024: Advancing the Safe, Effective and Equitable Use of AI in Healthcare (Mark Sendak, MD, MPP; Suresh Balu, MD, MBA)

Rethinking Clinical Trials

           Speakers Mark Sendak, MD, MPP Population Health & Data Science lead Duke Institute for Health Innovation (DIHI) Suresh Balu, MD, MBA Director, Duke Institute for Health Innovation (DIHI) Associate Dean, Innovation and Partnership Duke School of Medicine Slides Keywords AI, ML, health equity Key Points The Duke Institute for Health Innovation’s (DIHI) mission is to catalyze transformative innovation in health and healthcare through high-impact research, leadership develo

article thumbnail

Millions of people to view digital prescriptions via the NHS app

Pharma Times

Prescriptions ordered via the app are expected to save around 1.

132
132
article thumbnail

Ascidian launches first-ever clinical study of RNA exon editor for vision loss

Pharmaceutical Technology

An eye-catching milestone in hand, Ascidian will begin the Phase I/II STELLAR study of ACDN-01 for Stargardt disease in H1 2024.

RNA 261
article thumbnail

Roche shuffles early stage pipeline as it joins obesity rush

Bio Pharma Dive

Roche said it was shelving those drugs in favor of experimental programs to treat obesity that it gained from its takeover of Carmot Therapeutics.

Drugs 310
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

FDA sets date for high-profile CAR-T adcomm for Bristol’s Abecma, J&J’s Carvykti

Fierce Pharma

Mark your calendars, oncology drug and CAR-T therapy developers. | Mark your calendars, oncology drug and CAR-T therapy developers. The FDA has decided on a date for a highly anticipated advisory committee meeting for Bristol Myers' Abecma and J&J's Carvykti.

article thumbnail

Hybrid and multi-cloud: The next step for biotech to secure flexible, scalable scientific workflows

pharmaphorum

Hybrid and multi-cloud: The next step for biotech to secure flexible, scalable scientific workflows Mike.

129
129
article thumbnail

Bristol Myers Squibb’s Abecma recommended for EU approval

Pharmaceutical Technology

The EMA CHMP has recommended marketing authorisation for Bristol Myers Squibb’s Abecma for multiple myeloma.

Marketing 261
article thumbnail

Cour gets $105M, pharma help to ‘reprogram’ autoimmune disease

Bio Pharma Dive

Roche, Pfizer and Bristol Myers Squibb have all invested in the startup, which is using nanoparticle technology to retrain the body’s immune system.

305
305
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.